Trending NewsTrending NewsNASDAQ:RXRX Recursion Pharmaceuticals (RXRX) Stock Price, News & Analysis $2.83 +0.11 (+4.04%) Closing price 04:00 PM EasternExtended Trading$2.87 +0.04 (+1.52%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Recursion Pharmaceuticals Stock (NASDAQ:RXRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get RXRX alerts:Sign Up Key Stats Today's Range$2.77▼$3.0250-Day Range$2.72▼$4.7852-Week Range$2.50▼$5.24Volume41.16 million shsAverage Volume21.37 million shsMarket Capitalization$1.76 billionP/E RatioN/ADividend YieldN/APrice Target$7.52Consensus RatingHold Company Overview Recursion Pharmaceuticals, Inc. is a biotechnology company that uses automation, large-scale biological and chemical data, and machine learning to discover and develop medicines. Its platform, known as Recursion OS, is designed to identify relationships between biological processes and potential treatments. The company develops drug candidates for areas including rare diseases and oncology, and it also works with pharmaceutical partners on drug discovery and development. Its research combines laboratory experiments with computational analysis to evaluate potential therapeutic targets and compounds. Founded in 2013 and headquartered in Salt Lake City, Utah, Recursion was co-founded by Chris Gibson, who serves as its chief executive officer. The company expanded its drug-discovery capabilities through its 2024 acquisition of Exscientia, a UK-based biotechnology company focused on AI-enabled drug discovery.AI Generated. May Contain Errors. Read More Recursion Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreRXRX MarketRank™: 2.96386851399 of 5 starsRecursion Pharmaceuticals scored higher than 59% of companies evaluated by MarketBeat, and ranked 615th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingHold Consensus RatingRecursion Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialRecursion Pharmaceuticals has a consensus price target of $7.52, representing about 165.7% upside from its current price of $2.83.Amount of Analyst CoverageRecursion Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Recursion Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Recursion Pharmaceuticals are expected to grow in the coming year, from ($0.89) to ($0.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Recursion Pharmaceuticals is -3.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Recursion Pharmaceuticals is -3.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRecursion Pharmaceuticals has a P/B Ratio of 1.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted24.47% of the float of Recursion Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRecursion Pharmaceuticals has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Recursion Pharmaceuticals has recently decreased by 12.14%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRecursion Pharmaceuticals does not currently pay a dividend.Dividend GrowthRecursion Pharmaceuticals does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment-0.03 News SentimentRecursion Pharmaceuticals has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Recursion Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 19 people have searched for RXRX on MarketBeat in the last 30 days. This is a decrease of -54% compared to the previous 30 days.MarketBeat Follows22 people have added Recursion Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 214% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Recursion Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $701,276.00 in company stock.Percentage Held by Insiders6.65% of the stock of Recursion Pharmaceuticals is held by insiders.Percentage Held by Institutions89.06% of the stock of Recursion Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Recursion Pharmaceuticals' insider trading history. Receive RXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Recursion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RXRX Stock News HeadlinesStock Market Today, Nov. 18: Recursion Pharmaceuticals Rises 4% on FDA Alignment for REC-4881 Phase 3 DesignNovember 18 at 5:20 PM | fool.comWhy Recursion Pharmaceuticals Stock Is Up TodayNovember 18 at 12:03 PM | fool.comBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvidia's. A NASA scientist says the technology behind it is bigger than AI. Musk calls it "Amazing," and a Nobel Prize winner describes its power as "unprecedented in the history of life on Earth." Adam O'Dell, Chief Investment Strategist at Money and Markets, names the company at the center of it all.November 18 at 1:00 AM | Banyan Hill Publishing (Ad)Recursion Aligns With FDA On Phase 3 Trial Design For FAP Drug REC-4881; Stock UpNovember 18 at 9:59 AM | rttnews.comRecursion, FDA Align on Familial Adenomatous Polyposis Phase 3 Trial Design; Shares Up Pre-BellNovember 18 at 9:59 AM | marketscreener.comMRecursion Pharmaceuticals Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous PolyposisNovember 18 at 9:59 AM | marketscreener.comMThe AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom (RXRX)AI infrastructure is being funded with debt and stock sales while biotech companies applying AI are booking revenue, led by Tempus AI, Recursion and iShares Biotechnology...November 11, 2026 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Director Sells $155,200.00 in StockNovember 5, 2026 | insidertrades.comSee More Headlines RXRX Stock Analysis - Frequently Asked Questions How have RXRX shares performed this year? Recursion Pharmaceuticals' stock was trading at $4.09 at the beginning of 2026. Since then, RXRX stock has decreased by 30.8% and is now trading at $2.83. How were Recursion Pharmaceuticals' earnings last quarter? Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) released its quarterly earnings results on Monday, November, 2nd. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.00. The company earned $18.55 million during the quarter, compared to analyst estimates of $14.81 million. Recursion Pharmaceuticals had a negative net margin of 697.15% and a negative trailing twelve-month return on equity of 47.85%. Read the conference call transcript. When did Recursion Pharmaceuticals IPO? Recursion Pharmaceuticals (RXRX) raised $412 million in an initial public offering on Thursday, April 15th 2021. The company issued 24,242,424 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink, Allen & Co. and KeyBanc Capital Markets served as the underwriters for the IPO. Who are Recursion Pharmaceuticals' major shareholders? Recursion Pharmaceuticals' top institutional shareholders include State Street Corp (4.82%), Sumitomo Mitsui Trust Group Inc. (0.92%), First Trust Advisors LP (0.57%) and Goldman Sachs Group Inc. (0.52%). Insiders that own company stock include Blake Borgeson, Najat Khan, Michael Secora, Ben R Taylor, Christopher Gibson, Tina Marriott, Dean Y Li, Tina Marriott Larson, Robert Hershberg, Shafique Virani, Namandje Bumpus and Zavain Dar. View institutional ownership trends. How do I buy shares of Recursion Pharmaceuticals? Shares of RXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Recursion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Recursion Pharmaceuticals investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), SoundHound AI (SOUN), Tesla (TSLA), Micron Technology (MU) and Super Micro Computer (SMCI). Company Calendar Last Earnings11/02/2026Today11/18/2026Jefferies Global Healthcare Conference11/18/20269th Annual Evercore ISI HealthCONx Conference11/30/2026Citi Annual Global Healthcare Conference 202612/01/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 As of 2 days ago, RXRX's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RXRX CIK1601830 Webwww.recursion.com Phone385-269-0203Fax801-821-2872Employees600Year Founded2013Price Target and Rating Average Price Target for Recursion Pharmaceuticals$7.52 High Price Target$11.00 Low Price Target$5.60 Potential Upside/Downside+165.7%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$644.76 million Net Margins-697.15% Pretax Margin-703.83% Return on Equity-47.85% Return on Assets-36.26% Debt Debt-to-Equity RatioN/A Current Ratio5.01 Quick Ratio5.01 Sales & Book Value Annual Sales$74.68 million Price / Sales23.60 Cash FlowN/A Price / Cash FlowN/A Book Value$1.45 per share Price / Book1.95Miscellaneous Outstanding Shares622,760,000Free Float581,346,000Market Cap$1.76 billion OptionableOptionable Beta1.15 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:RXRX) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.